Genmab — Marts 2024
-
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons https://www.proinvestor.com/investornyt/1126869/transactions-with-shares-and-linked-securities-in-genmab-a-s-made-by-managerial-employees-and-their-closely-associated-persons
-
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons https://ir.genmab.com/news-releases/news-release-details/transactions-shares-and-linked-securities-genmab-made-61
-
Hold the Press!!! Is that an insider purchase in the open market?
-
Servicemeddelelse. Marketwire har tekniske udfordringer her til morgen og leverer derfor ikke nyheder til vort feed.
-
An Antibody–Drug Conjugate Directed to Tissue Factor Shows Preclinical Antitumor Activity in Head and Neck Cancer as a Single Agent and in Combination with Chemoradiotherapy / Tisotumab - https://aacrjournals.org/mct/article-abstract/23/2/187/733943/An-Antibody-Drug-Conjugate-Directed-to-Tissue?redirectedFrom=fulltext
-
the GEN1046 Endometrial trial ads a few more trial centers , Cohort A closed already, could this be a sign of quick recruitment? https://classic.clinicaltrials.gov/ct2/history/NCT06046274?A=7&B=8&C=Side-by-Side#StudyPageTop
-
separate new Epcoritamab trial by the Australasian Leukaemia and Lymphoma Group https://clinicaltrials.gov/study/NCT06287398
-
Lundbeck presents encouraging results from the Lu AF82422 trial for Multiple System Atrophy at the international AD/PD 2024 conference on neurodegenerative disorders https://news.cision.com/h--lundbeck-a-s/r/lundbeck-presents-encouraging-results-from-the-lu-af82422-trial-for-multiple-system-atrophy-at-the-i,c3940069
-
Thanks E L .
-
not sure i ever heard of Baader Bank, but it seems they have a buy - Genmab $GMAB 1,954DKK
Baader. Buy. 3,239
️ 3,446DKK https://twitter.com/Quality_stocksA/status/1764913792394129790 -
I meddelelsen fra Genmab angives kurs 27,881, og handelsdato 28. feb.
-
Lundbeck gør klar til fase 3-studie af MSA-middel efter opmuntrende data
Lundbeck bekræfter sine planer om at gå i fase 3 med en kandidat mod multipel system atrofi. https://medwatch.dk/Medicinal___Biotek/article16905404.ece
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind